

Justyna Siwy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7854460/publications.pdf>

Version: 2024-02-01

67
papers

3,214
citations

172457

29
h-index

161849

54
g-index

72
all docs

72
docs citations

72
times ranked

3735
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2014-2021.	0.7	4
2	Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0262667.	2.5	12
3	Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Toxins</i> , 2022, 14, 10.	3.4	15
4	Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000027.	1.6	29
5	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 811-818.	0.7	26
6	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1690.	2.4	10
7	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. <i>Kidney International</i> , 2021, 99, 1240-1241.	5.2	2
8	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. <i>EClinicalMedicine</i> , 2021, 36, 100883.	7.1	28
9	A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease. <i>Proteomes</i> , 2021, 9, 32.	3.5	21
10	CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology?. <i>Proteomics</i> , 2021, 21, e2100133.	2.2	16
11	SGLT2 inhibition reverts urinary peptide changes associated with severe COVID-19: An in silico proof of principle of proteomics-based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	2.2	3
12	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 42-52.	0.7	36
13	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e690-e703.	4.6	17
14	Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS. <i>Molecules</i> , 2021, 26, 7260.	3.8	28
15	Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. <i>Proteomes</i> , 2021, 9, 49.	3.5	5
16	A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves. <i>Pediatric Nephrology</i> , 2020, 35, 469-475.	1.7	17
17	MO041 URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	7
18	Proteomic characterization of obesity-related nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 684-692.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. <i>Scientific Reports</i> , 2020, 10, 8291.	3.3	10
20	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	11.4	166
21	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. <i>Methods in Molecular Biology</i> , 2020, 2067, 287-306.	0.9	3
22	Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 853-856.	3.1	9
23	Proteomics and personalized medicine: a focus on kidney disease. <i>Expert Review of Proteomics</i> , 2019, 16, 773-782.	3.0	15
24	Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. <i>Electrophoresis</i> , 2019, 40, 2294-2308.	2.4	89
25	Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 169-182.	1.1	41
26	Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-2D Trial. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800144.	1.6	22
27	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700163.	1.6	38
28	Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. <i>Scientific Reports</i> , 2018, 8, 5584.	3.3	19
29	Urinary CE-MS peptide marker pattern for detection of solid tumors. <i>Scientific Reports</i> , 2018, 8, 5227.	3.3	28
30	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.7	73
31	Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw243.	0.7	25
32	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	62
33	Polymerization-Incompetent Uromodulin in the Pregnant Stroke-Prone Spontaneously Hypertensive Rat. <i>Hypertension</i> , 2017, 69, 910-918.	2.7	11
34	Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1468-1477.	0.7	16
35	Comparative proteome and peptidome analysis of the cephalic fluid secreted by <i>Arapaima gigas</i> (Teleostei: Osteoglossidae) during and outside parental care. <i>PLoS ONE</i> , 2017, 12, e0186692.	2.5	18
36	Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. <i>Kidney International</i> , 2016, 90, 1045-1055.	5.2	31

#	ARTICLE	IF	CITATIONS
37	Proteomics of vitreous in neovascular age-related macular degeneration. <i>Experimental Eye Research</i> , 2016, 146, 107-117.	2.6	36
38	Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion. <i>PLoS ONE</i> , 2016, 11, e0158001.	2.5	21
39	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	6.1	205
40	Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation. <i>Liver International</i> , 2015, 35, 1893-1901.	3.9	6
41	Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 44-54.	4.7	58
42	Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals. <i>Current Protein and Peptide Science</i> , 2014, 15, 23-35.	1.4	14
43	Urinary proteomics in obstructive sleep apnoea and obesity. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1104-1115.	3.4	14
44	Urine as a source for clinical proteome analysis: From discovery to clinical application. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 884-898.	2.3	84
45	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
46	Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration. <i>PLoS ONE</i> , 2014, 9, e96895.	2.5	74
47	Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV). <i>Science Translational Medicine</i> , 2013, 5, 198ra106.	12.4	86
48	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	2.2	21
49	High-Resolution Proteome/Peptidome Analysis of Body Fluids by Capillary Electrophoresis Coupled with MS. <i>Methods in Molecular Biology</i> , 2013, 984, 153-165.	0.9	12
50	Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. <i>PLoS ONE</i> , 2013, 8, e53016.	2.5	70
51	Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. <i>PLoS ONE</i> , 2013, 8, e66682.	2.5	23
52	Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease. <i>PLoS ONE</i> , 2013, 8, e67514.	2.5	43
53	Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice. <i>PLoS ONE</i> , 2013, 8, e76703.	2.5	50
54	CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis. <i>PLoS ONE</i> , 2013, 8, e62837.	2.5	125

#	ARTICLE	IF	CITATIONS
55	Urinary Proteome Analysis at 5-Year Followup of Patients With Nonoperated Ureteropelvic Junction Obstruction Suggests Ongoing Kidney Remodeling. <i>Journal of Urology</i> , 2012, 187, 1006-1011.	0.4	31
56	Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. <i>PLoS ONE</i> , 2012, 7, e51334.	2.5	59
57	Performance of different separation methods interfaced in the same MSâ€reflection TOF detector: A comparison of performance between CE versus HPLC for biomarker analysis. <i>Electrophoresis</i> , 2012, 33, 567-574.	2.4	29
58	Proteomic Candidate Biomarkers of Drug-Induced Nephrotoxicity in the Rat. <i>PLoS ONE</i> , 2012, 7, e34606.	2.5	24
59	Human urinary peptide database for multiple disease biomarker discovery. <i>Proteomics - Clinical Applications</i> , 2011, 5, 367-374.	1.6	105
60	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. <i>Hepatology</i> , 2011, 53, 875-884.	7.3	143
61	Urinary Proteomics for Prediction of Preeclampsia. <i>Hypertension</i> , 2011, 57, 561-569.	2.7	129
62	A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy. <i>PLoS ONE</i> , 2011, 6, e20534.	2.5	22
63	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 464-478.	1.6	139
64	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. <i>PLoS ONE</i> , 2010, 5, e13051.	2.5	51
65	The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. <i>Proteomics</i> , 2009, 9, 2108-2117.	2.2	82
66	Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. <i>Journal of Proteome Research</i> , 2009, 8, 268-281.	3.7	221
67	Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11299-11304.	7.1	151